

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Rafat Abonour, M.D.		POSITION TITLE Professor of Medicine	
eRA COMMONS USER NAME (credential, e.g., agency login) rabonour			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Damascus-Syria	M.D.	07/1984	Medicine

**A. Personal statement**

I have been active in clinical research for the last 15 years at Indiana University and my work has been published in Nature Medicine and New England Journal of Medicine among others. My role as a leader of the Multiple Myeloma program has allowed me to participate in practice changing research using IMiD's and Proteasome inhibitors. I have been facilitating clinical research at the IU Simon Cancer Center and IU School of Medicine for the last eight years. I help investigators navigate the arena of clinical research and mentor them to help increase the number of patients' participation in clinical research.

**B. Position and Honors**

- 1983-1984 Intern, Internal Medicine, Medical Care Center, Damascus, Syria
- 1985-1989 Postdoctoral Fellowship, Immunology, University Of Wisconsin, Madison, WI
- 1989-1991 Resident, Internal Medicine (PG1,2), University of Wisconsin, Milwaukee Campus, Milwaukee, WI
- 1991-1992 Resident, Internal Medicine (PG3), University of Wisconsin, Madison, WI
- 1992-1994 Hematology Fellowship, University of Wisconsin, Madison, WI
- 1992-1994 Postdoctoral Fellowship (NIH; HL07684), University of Wisconsin, Madison, WI
- 1994-1995 Clinical Instructor, University of Wisconsin, Madison, WI
- 1995-2001 Assistant Professor of Medicine, Indiana University, Indianapolis, IN
- 1997-2001 Assistant Professor of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN
- 2001-Pres Associate Professor of Medicine, Indiana University, Indianapolis, IN
- 2001-Pres Associate Professor of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN
- 2005-Pres Associate Dean for Clinical Research, Indiana University, Indianapolis, IN

**OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:**

- 1995-Pres Medical Director, Stem Cell Laboratory, IU Medical Center, Indianapolis, IN
- 1995-2005 Chair, Institutional Review Board, Indiana University School of Medicine, Indianapolis IN
- 1996-Pres Member, Scientific Research Committee, Indiana University Cancer Center, Indianapolis, IN
- 1996-2001 Member, Gene Therapy Working Group, Indiana University Medical School, Indianapolis, IN
- 1997-Pres Member, General Clinical Research Center Advisory Committee, Indiana University Medical Center, Indianapolis, IN
- 1997-2004 Member, Medical Advisory Committee of Central Indiana Regional Blood Center, Indianapolis, IN
- 1999-2002 Member, IUPUI Faculty Council, Indianapolis, IN
- 2000-Pres Member, Executive Committee of Institutional Review Board, Indiana University, Indianapolis,

IN  
2000-Pres Member of the Board, University Medical Diagnostic Association, Indiana University, Indianapolis, IN  
2001-2006 Director, IU Bone Marrow and Stem Cell Transplantation Program, Indiana University, Indianapolis, IN  
2010-2012 Director, Hoosier Oncology Group, Indianapolis, IN  
2008-Pre Director, Clinical Research Office, Indiana University, Indianapolis, IN  
2010-Pre President, IUPUI Faculty Steering Committee, Indianapolis, IN

HONORS:

1994 Special Initiative in Molecular Medicine. U Wisconsin-Madison  
1990 Winner, American College of Physicians, National Associate Clinical Poster Competition  
1989-1990 Outstanding Junior Resident, U. Wisconsin, Milwaukee  
1989 Winner, Medical Research competition ACP-Wisconsin Regional Meeting, 1989  
1999 Winner of the Clinical Associate Physician Abstract Competition, GCRC National Meeting, Washington, D.C.  
2003 Glenn Irwin, Jr., M.D. Experience Excellence Award, Indiana University Purdue University, Indianapolis  
2006 Winner of the Indianapolis Business Journal Physician Health Care Hero Award  
2006 Winner of the Leukemia and Lymphoma Society, Indianapolis Chapter, Excellence in Cancer Care Award  
2007 Trustee Teaching Award. Indiana University

**C. Selected Peer-Review Publications (out of 45)**

1. **Abonour**, R, Scott, K.M., Kunkel, L.A., Robertson, M.J., Hromas, R., Graves, V., Lazaridis, E.N., Cripe, L., Gharpure, V., Traycoff, C.M., Mills, B., Srour, E.F., and Cornetta, K.: Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. *Bone Marrow Transplantation* 22:957-963, 1998.
2. **Abonour**, R., Williams, D.A., Einhorn, L., Hall, K.M., Chen, J., Coffman, J., Traycoff, C.M., Bank, A., Kato, I., Ward, M., Williams, S.D., Hromas, R., Robertson, M.J., Smith, F.O., Woo, D., Mills, B., Srour, E.F., and Cornetta, K.: Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem. *Nature Medicine* 6:652-58, 2000.
3. Croop J, Graves V, Williams DA, Cornetta K, and **Abonour** R. Large-scale mobilization and selection of CD34+ cells from normal donors. *Bone Marrow Transplantation* 26:1271-1280, 2000.
4. Plett PA, **Abonour** R, Frankovitz S, Srour EF, and Orschell-Traycoff CM. Increased nod/scid repopulating potential and primitive hematopoietic function of human CD34+ cells following exposure to anti-CXCR4. *Experimental Hematology*, 2000.
5. Plett PA, Frankovitz S, Jetmore A, **Abonour** R, and Orschell-Traycoff CM. Proliferation and functional characterization of human CD34+ bone marrow cells cultured in simulated microgravity. *Experimental Hematology*, 2000.
6. **Abonour** R, Benson M.D., Robertson M.J., Hromas R, Cornetta K. Tandem intermediate dose melphalan supported by autologous progenitor cells in the management of primary amyloidosis. *Blood Supplement* 2000.
7. Vidarsson B, **Abonour** R, Williams EC, Woodson RD, Turman NJ, Kim KM, Mosher DF, Wiersma SR, Longo WL. Fludarabine and Cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. *Leukemia & Lymphoma*. 41(3-4):321-31, 2001.
8. Vaena DA, **Abonour** R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies which adverse prognostic variables. *Journal of Clinical Oncology*, 21(22):4100-04, 2003.
9. Gertz MA, Blood E, Vesole DH, **Abonour** R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. *Bone Marrow Transplant*, 34(2):149-54, 2004.
10. Srour EF, Tong X, Sung KW, Plett PA, Rice S, Daggy J, Yiannoutsos CT, **Abonour** R, Orschell CM. Modulation of in vitro proliferation kinetics and primitive hematopoietic potential of individual human

CD34+CD38-/lo cells in G0. Blood. 2005 Apr 15;105(8):3109-16

11. Cai S, Hartwell JR, Cooper RJ, Juliar BE, Kreklau E, **Abonour** R, Goebel WS, Pollok KE. In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human GCSF-mobilized peripheral blood cells. Mol Ther. 2006 May;13(5):1016-26.
12. Suvannasankha A, Smith GG, Juliar BE, **Abonour** R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006 Sep;7(2):131-4.
13. Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, **Abonour** R. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist. 2007 Jan;12(1):99-106.
14. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, **Abonour** R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007 Jul 26;357(4):340-8.
15. Suvannasankha A, Crean CD, Shanmugam R, Farag SS, **Abonour** R, Boswell HS, Nakshatri H. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res. 2008 Mar 15;14(6):1814-22.
16. Wang X, Sinn AL, Pollok K, Sandusky G, Zhang S, Chen L, Liang J, Crean CD, Suvannasankha A, **Abonour** R, Sidor C, Bray MR, Farag SS. Preclinical activity of a novel multiple tyrosen kinase and aurora kinas inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010 Agu; 150(3): 313-25. Epub 2010 Jun 15. PMID: 20560971
17. Agarwal AK, Perkins SM, **Abonour** R, Brames MJ, Einhorn, LH. Salvage Chemotherapy with High-Dose Carboplatin and Etoposide with Peripheral Blood Stem Cell Transplantation in Patients with Relapsed Pure Seminoma. Am J Clin Oncol. 2010 Jun 2. [Epub ahead of print] PMID: 20523207.

#### D. Research Support

**P30 CA082709-14S3 (Loehrer, P.) 09/01/08 - 8/31/14**

**NIH/NCI**

**Cancer Center Support Grant**

Role: Director, Clinical Research Office

The major goal of this project is to establish an NCI designated Cancer Center by facilitating cancer research, education, patient care, and cancer control and prevention to accomplish its mission of reducing the incidence, morbidity, and mortality of cancer.

**(Abonour, R.) 3/11/10 – 3/11/14**

**Celgene Corporation**

**Connect MM: The Multiple Myeloma disease registry**

The major goal of this project is to establish a large database of newly diagnosed patient and to follow their natural history for 5 years.

**KL2 TR000163 (Shekhar, A.) 05/01/13 – 04/30/14**

**NIH-NCATS**

**Indiana Clinical and Translational Sciences Institute – Cooperative Agreement, Year 6**

Role: Co-Investigator

The major goal of this project is to facilitate the translation of scientific discoveries in the lab into clinical trials and new patient treatments in Indiana and beyond.

#### Completed:

**(Wang, M.) 6/1/08 – 05/31/11**

**Multiple Myeloma Research Foundation**

**Biomarker Discovery and Validation in Multiple Myeloma Cells Using Multiple Proteomic Platforms**

The major goal of this application is to apply state of the art proteomic technologies to identify and validate potential biomarker candidates of multiple myeloma.

Role: Co-Investigator